ALZAMEND NEURO INC (ALZN) Stock Income Statement
USA - NASDAQ:ALZN - US02262M6057 - Common Stock
2.38 USD
-0.14 (-5.56%)
| TTM (2025-7-31) | 2025 (2025-4-30) | 2024 (2024-4-30) | 2023 (2023-4-30) | 2022 (2022-4-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 6.23M | 4.50M | 9.94M | 14.87M | 12.32M | |||
| Research and Development | 2.95M | 1.41M | 6.46M | 7.45M | 5.20M | |||
| Selling, General, and Administrative Expenses | 3.29M | 3.08M | 3.48M | 7.42M | 7.12M | |||
| Operating Income | -6.23M | -4.50M | -9.94M | -14.87M | -12.32M | |||
| Interest Income/Expense | -8.50K | -18.00K | -10.10K | -10.00K | -50.00K | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | null | null | 0 | 0 | |||
| Income Before Taxes | -6.24M | -4.51M | -9.95M | -14.88M | -12.36M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -6.89M | -5.11M | -9.95M | -14.88M | -12.36M | |||
| EBITDA | -6.17M | -4.45M | -9.89M | -14.85M | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -9.017 | -11.3245 | -132.3311 | -205.98 | -187.27 | |||
| Non GAAP EPS | null | null | -247.95000000000002 | -202.5 | null | |||
| Statistics | ||||||||
All data in USD